Search

Author/Creator Cataland, S.

1. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. (5th June 2017)

Authors:
Peyvandi, F.; Scully, M.; Kremer Hovinga, J. A.; Knöbl, P.; Cataland, S.; De Beuf, K.; Callewaert, F.; De Winter, H.; Zeldin, R. K.
Journal:
Journal of thrombosis and haemostasis
Issue:
Volume 15:Number 7(2017)
Page Start:
1448
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. (30th January 2017)

Authors:
Scully, M.; Cataland, S.; Coppo, P.; de la Rubia, J.; Friedman, K. D.; Kremer Hovinga, J.; Lämmle, B.; Matsumoto, M.; Pavenski, K.; Sadler, E.; Sarode, R.; Wu, H.
Other Names:
Gale D. investigator.; Fujimura Y. investigator.; McDonald V. investigator.; Peyvandi F. investigator.; Scharrer I. investigator.; Veyradier A. investigator.; Westwood J. P. investigator.
Journal:
Journal of thrombosis and haemostasis
Issue:
Volume 15:Number 2(2017)
Page Start:
312
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. S294: LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST-HERCULES STUDY. (23rd June 2022)

Authors:
Scully, M.; de la Rubia, J.; Pavenski, K.; Metjian, A.; Knöbl, P.; Peyvandi, F.; Cataland, S.; Coppo, P.; Kremer Hovinga, J. A.; De Passos Sousa, R.; Callewaert, F.; Gunawardena, S.; Lin, J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
195
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗